Asarina Pharma is developing novel and targeted products to treat women with severe symptoms associated with the menstrual cycle such as premenstrual dysphoric disorder (PMDD), allowing these women to remain in control of their own life.
Location: Sweden, Botkyrka kommun
Employees: 1-10
Total raised: $7.73M
Founded date: 2006
Investors 2
| Date | Name | Website |
| - | Idinvest P... | idinvest.c... |
| - | Kurma Part... | kurmapartn... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 07.11.2016 | - | $7.73M | - |
Mentions in press and media 21
| Date | Title | Description |
| 05.05.2023 | Asarina Pharma’s positive Phase IIa Tourette Syndrome results to be presented at TicCon, the Virtual National Conference of the Tourette Association of America | Asarina Pharma’s positive Phase IIa Tourette Syndrome results to be presented at TicCon, the Virtual National Conference of the Tourette Association of America Fri, May 05, 2023 13:33 CET Report this content (Stockholm, May 5, 2023) On May ... |
| 28.04.2023 | Asarina Pharma AB (publ) releases Annual Report 2022 | Asarina Pharma AB (publ) releases Annual Report 2022 Fri, Apr 28, 2023 20:30 CET Report this content (Stockholm, 28 April 2023) Asarina Pharma’s 2022 Annual Report contains analysis and insights into its recent positive Phase IIa results fo... |
| 01.04.2023 | Asarina Pharma publishes positive results from its Phase IIa study of Sepranolone in Tourette Syndrome | Asarina Pharma publishes positive results from its Phase IIa study of Sepranolone in Tourette Syndrome Sat, Apr 01, 2023 14:20 CET Report this content (Stockholm, April 1, 2023) Asarina Pharma today releases results from its Phase IIa study... |
| 27.02.2023 | Asarina Pharma AB (publ) releases Year-End Report 2022 | Asarina Pharma AB (publ) releases Year-End Report 2022 Mon, Feb 27, 2023 08:30 CET Report this content (Stockholm, 27 February 2023.) Asarina Pharma today announces that it has released its Year End Report 2022. In the second half of 2022 t... |
| 02.02.2023 | Last Patient Last Visit for landmark Tourette Syndrome study | Last Patient Last Visit for landmark Tourette Syndrome study Thu, Feb 02, 2023 09:45 CET Report this content (Stockholm, 2 February 2023.) The Last Patient’s Last Visit took place on 1 February less than 12 months after the study’s initiati... |
| 05.09.2022 | Asarina Pharma AB: new US CDC study suggests prevalence of Tourette significantly higher than previously thought | Asarina Pharma AB: new US CDC study suggests prevalence of Tourette significantly higher than previously thought Mon, Sep 05, 2022 13:24 CET Report this content A new study by the U.S. CDC (Centers for Disease Control and Prevention) estima... |
| 25.08.2022 | Asarina Pharma AB (publ) Q2 2022 Report released | Asarina Pharma AB (publ) Q2 2022 Report released Thu, Aug 25, 2022 08:30 CET Report this content CEO Peter Nordkild: “We are pleased to report continued progress in our Phase II study in Sepranolone for the treatment of Tourette in the seco... |
| 25.05.2022 | Asarina Pharma AB (publ) Q1 2022 Report released | Asarina Pharma AB (publ) Q1 2022 Report released Wed, May 25, 2022 08:30 CET Report this content Peter Nordkild, CEO: “Strong, steady progress best sums up Q1 2022. In a productive Quarter we have kept steadfastly to the recruitment goals o... |
| 06.04.2022 | ASARINA PHARMA AB (publ) ANNUAL REPORT 2021 RELEASED | ASARINA PHARMA AB (publ) ANNUAL REPORT 2021 RELEASED Wed, Apr 06, 2022 17:25 CET Report this content Peter Nordkild, CEO: “Despite the challenges of the last year we remain committed to our goal of providing new effective therapy to patient... |
| 24.02.2022 | Asarina Pharma AB (publ) Year-end Report 2021 released | Asarina Pharma AB (publ) Year-end Report 2021 released Thu, Feb 24, 2022 08:00 CET Report this content Peter Nordkild, CEO: “We enter the new financial year with renewed energy and optimism after Region Hovedstaden finally signed the requir... |
Show more